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ffect of Door-to-Balloon
ime on Mortality in Patients With
T-Segment Elevation Myocardial Infarction
obert L. McNamara, MD, MHS,* Yongfei Wang, MS,* Jeph Herrin, PHD,* Jeptha P. Curtis, MD,*
lizabeth H. Bradley, PHD,† David J. Magid, MD, MPH,§ Eric D. Peterson, MD, MPH,¶
artha Blaney, PHARMD,# Paul D. Frederick, PHD,** Harlan M. Krumholz, MD, SM,*†‡††
or the NRMI Investigators
ew Haven, Connecticut; Denver, Colorado; Durham, North Carolina; South San Francisco, California;
nd Seattle, Washington
OBJECTIVES We sought to determine the effect of door-to-balloon time on mortality for patients with
ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous
coronary intervention (PCI).
BACKGROUND Studies have found conflicting results regarding this relationship.
METHODS We conducted a cohort study of 29,222 STEMI patients treated with PCI within 6 h of
presentation at 395 hospitals that participated in the National Registry of Myocardial
Infarction (NRMI)-3 and -4 from 1999 to 2002. We used hierarchical models to evaluate the
effect of door-to-balloon time on in-hospital mortality adjusted for patient characteristics in
the entire cohort and in different subgroups of patients based on symptom onset-to-door time
and baseline risk status.
RESULTS Longer door-to-balloon time was associated with increased in-hospital mortality (mortality
rate of 3.0%, 4.2%, 5.7%, and 7.4% for door-to-balloon times of 90 min, 91 to 120 min,
121 to 150 min, and 150 min, respectively; p for trend 0.01). Adjusted for patient
characteristics, patients with door-to-balloon time 90 min had increased mortality (odds
ratio 1.42; 95% confidence interval [CI] 1.24 to 1.62) compared with those who had
door-to-balloon time 90 min. In subgroup analyses, increasing mortality with increasing
door-to-balloon time was seen regardless of symptom onset-to-door time (1 h, 1 to 2 h,
2 h) and regardless of the presence or absence of high-risk factors.
CONCLUSIONS Time to primary PCI is strongly associated with mortality risk and is important regardless of
time from symptom onset to presentation and regardless of baseline risk of mortality. Efforts
to shorten door-to-balloon time should apply to all patients. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.0722180–6) © 2006 by the American College of Cardiology Foundation
t
d
a
o
H
m
t
c
h
r
t
o
g
l
S
R
M
Sime to reperfusion for patients with ST-segment elevation
yocardial infarction (STEMI) consistently predicts mortality
or fibrinolytic therapy (1–3). In contrast, studies have found
onflicting results regarding the relationship between mortality
nd time to reperfusion with primary percutaneous coronary
ntervention (PCI). Some investigators have found lower
ortality for shorter symptom onset-to-reperfusion time for all
atients (4) or just certain subgroups such as high-risk patients
5) or those presenting within 2 h of symptom onset (6). Other
tudies found no lower mortality for shorter symptom onset-
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005, accepted December 19, 2005.o-balloon time but did find lower mortality for shorter
oor-to-balloon time (7,8). Finally, some studies failed to find
n association between either symptom onset-to-balloon time
r door-to-balloon time and mortality (9,10).
Although the American College of Cardiology/American
eart Association (ACC/AHA) guidelines for manage-
ent of patients with STEMI recommend door-to-balloon
imes of 90 min or less (11,12), a minority of patients are
urrently treated within this time period, and this pattern
as not changed recently (13). The perception that time to
eperfusion is less important in PCI (9,10) may contribute
o the current inertia in performance. To evaluate the effect
f door-to-balloon time on mortality in these patient
roups, we used detailed patient-level and hospital-level
ongitudinal data from a national sample of patients with
TEMI admitted from 1999 to 2002 from the National
egistry of Myocardial Infarction (NRMI)-3 and -4 (14).
ETHODS
tudy design and sample. We used NRMI, a voluntary
cute myocardial infarction (AMI) registry sponsored by
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June 6, 2006:2180–6 Door-to-Balloon Time and Mortalityenentech Inc. (South San Francisco, California), to define
cohort of patients with STEMI who received acute
eperfusion therapy with primary PCI. The NRMI criteria
15,16) include a diagnosis of AMI according to the
nternational Classification of Diseases, Ninth Revision, Clin-
cal Modification (code 410.X1) and any one of the following
riteria: total creatine kinase or creatine kinase-MB that was
wo or more times the upper limit of the normal range or
levations in alternative cardiac markers; electrocardio-
raphic evidence of AMI or nuclear medicine testing,
chocardiography, or autopsy evidence of AMI. During our
tudy period of January 1, 1999, to December 31, 2002,
here were 830,473 AMI admissions in NRMI. The fol-
owing patients were excluded sequentially: patients trans-
erred to or from another acute care institution (n 
41,730); with neither ST-segment elevation (2 leads) nor
eft bundle branch block on the first electrocardiogram
ECG) (n  334,013); with AMI symptom onset after the
dmission date and time (n  4,305); with a nondiagnostic
rst ECG (e.g., the first ECG did not show ST-segment
levation or left bundle branch block; n  14,314); with
iagnostic ECG that preceded hospital presentation by
ore than 1 h (prehospital ECG), or with time from
oor-to-diagnostic ECG that was more than 6 h or missing
n 6,467); who did not receive primary PCI (n 92,772);
ith door-to-balloon times that were negative, more than
h, or missing (n  925); and with unknown time of
ymptom onset (n  4,804). In addition, to avoid including
ospitals that performed primary PCI uncommonly, pa-
ients treated in hospitals reporting fewer than 20 PCI
atients over the four-year time period (n  1,921) were
xcluded. The final cohort included 29,222 patients from
95 hospitals. Mortality status at the time of discharge was
nown for all patients.
ata collection and measures. Our outcome was in-
ospital mortality, and the principal independent variable was
oor-to-balloon time, which is the time from hospital arrival to
alloon inflation, derived from the corresponding date/time
oted in the medical record and recorded in the NRMI case
eport form. Patients were stratified based on their time from
ymptom onset-to-door time (1 h, 1 to 2 h, 2 h) and
hether they had ACC/AHA high-risk factors (anterior/
eptal location, diabetes mellitus, heart rate 100 beats/min,
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
AMI  acute myocardial infarction
CI  confidence interval
ECG  electrocardiogram
NRMI  National Registry of Myocardial Infarction
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarctionystolic blood pressure 100 mm Hg) (11). sOther patient-level variables included age (65 years, 65
o 79 years,80 years), gender, race/ethnicity (white, black,
ispanic, other), insurance status, and clinical characteris-
ics. Clinical characteristics consisted of medical history
current smoker, chronic renal insufficiency, previous AMI,
ypertension, family history of coronary artery disease,
ypercholesterolemia, congestive heart failure, previous per-
utaneous transluminal coronary angioplasty, previous cor-
nary artery bypass graft surgery, chronic obstructive pul-
onary disease, stroke, angina, diabetes); presentation
haracteristics (time from symptom onset-to-presentation,
hether a prehospital ECG was performed, the admission
ime of day [day, evening, or night], admission day of week
weekday or weekend], chest pain at presentation, systolic
lood pressure, heart rate, heart failure); and the results of
he diagnostic ECG (number of leads with ST-segment
levation, AMI location, ST-segment depression, nonspe-
ific ST/T-wave changes, Q-wave). Calendar time, mea-
ured as the number of days between January 1, 1999, and
he hospital admission date, was included as an independent
ariable to account for any secular trends as well as for
iffering reporting periods by hospitals.
tatistical analysis. We first examined the bivariate asso-
iation between patient characteristics and in-hospital mor-
ality, using chi-square tests to assess for the association
etween categorical variables and in-hospital mortality and
tests or F tests to assess for the association between
ontinuous variables and in-hospital mortality.
We then examined the bivariate association between
oor-to-balloon time and in-hospital mortality with door-
o-balloon time as a categorical variable. We did this for the
hole cohort and stratified by symptom onset-to-door time
1 h, 1 to 2 h, 2 h) and presence or absence of
nterior/septal location, diabetes mellitus, heart rate 100
eats/min, systolic blood pressure100 mm Hg, and any of
hese baseline risk factors.
For the independent effect of door-to-balloon time on
n-hospital mortality, we used a multivariable logistic re-
ression model using in-hospital death as the dependent
ariable. Because NRMI enrolls hospitals that then report
atients, we could not assume that measurements were
ndependent of hospital; assessment of intraclass correla-
ions indicated that variation in both time to treatment (p
.1099, 95% CI 0.0916 to 0.1282) and mortality (p 
.0084, 95% CI 0.0052 to 0.0434) was partly explained by
ospital. Thus, we used hierarchical models to account for
lustering of patients within hospitals. Random effects were
pecified for the main intercept and the coefficients of
alendar time in the model. We replicated the model in all
he strata of symptom onset-to-door time and baseline risk
actors, as defined above; the stratification variable was not
ncluded in the corresponding subgroup model. We also
stimated a final set of models using the whole cohort, each
f which included the interaction between door-to-balloon
ime and one of these stratification variables. We performed
econdary analyses that included the 2.0% of patients
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Door-to-Balloon Time and Mortality June 6, 2006:2180–6able 1. Patient Characteristics, Door-to-Balloon Time, and In-Hospital Mortality
Description
Prevalence
n (%)
Door-to-Balloon Time
Mortality
Median, min
(Quartile Range) p n (%) p
ll 29,222 (100.00) 102 (54) 1,329 (4.55)
emographics
Age 0.0001 0.0001
65 yrs 17,314 (59.25) 99 (52) 356 (2.06)
65–80 yrs 9,425 (32.25) 106 (56) 623 (6.61)
80 yrs 2,483 (8.50) 115 (59) 350 (14.10)
Gender
Male 20,712 (70.88) 100 (52) 0.0001 739 (3.57) 0.0001
Female 8,510 (29.12) 108 (57) 590 (6.93)
Race 0.0001 0.7847
White 25,082 (85.83) 101 (53) 1,147 (4.57)
Black 1,428 (4.89) 118 (63) 58 (4.06)
Hispanic 971 (3.32) 114 (61) 47 (4.84)
Other 1,741 (5.96) 102 (52) 77 (4.42)
Health insurance 0.0001 0.0001
Medicare only 5,218 (17.86) 107 (58) 397 (7.61)
Medicare and (commercial or other) 5,037 (17.24) 107 (57) 381 (7.56)
Medicare and Medicaid 473 (1.62) 113 (62) 51 (10.78)
Commercial 13,483 (46.14) 100 (52) 313 (2.32)
Medicaid only 751 (2.57) 104 (56) 37 (4.93)
Veterans Administration 156 (0.53) 95 (55) 6 (3.85)
Other 1,302 (4.46) 98 (53) 49 (3.76)
Self 2,502 (8.56) 97 (50) 80 (3.20)
Unknown 300 (1.03) 105 (61) 15 (5.00)
edical history
Current smoker 11,320 (38.74) 99 (52) 0.0001 282 (2.49) 0.0001
Chronic renal insufficiency 698 (2.39) 117 (65) 0.0001 109 (15.62) 0.0001
Diabetes mellitus 5,440 (18.62) 110 (59) 0.0001 380 (6.99) 0.0001
Previous myocardial infarction 4,800 (16.43) 106 (59) 0.0001 237 (4.94) 0.1565
Hypertension 14,218 (48.66) 105 (55) 0.0001 749 (5.27) 0.0001
Hypercholesterolemia 11,065 (37.87) 101 (54) 0.0124 327 (2.96) 0.0001
Family history of coronary artery disease 8,490 (29.05) 101 (53) 0.0005 230 (2.71) 0.0001
Congestive heart failure 913 (3.12) 118 (65) 0.0001 126 (13.80) 0.0001
Percutaneous coronary intervention 4,259 (14.57) 104 (57) 0.0032 150 (3.52) 0.0005
Coronary artery bypass 1,698 (5.81) 120 (65) 0.0001 109 (6.42) 0.0001
Chronic obstructive pulmonary disease 2,319 (7.94) 107 (58) 0.0001 152 (6.55) 0.0001
Stroke 1,357 (4.64) 114 (65) 0.0001 149 (10.98) 0.0001
Angina 2,312 (7.91) 105 (58) 0.0288 123 (5.32) 0.0633
resentation
Prehospital 12-lead ECG 2,915 (9.98) 83 (50) 0.0001 103 (3.53) 0.0056
Chest pain at presentation 0.0001
No 1,527 (5.23) 123 (73) 0.0001 336 (22.00)
Yes 27,375 (93.68) 101 (52) 0.0001 937 (3.42)
Unknown 320 (1.10) 111 (61) 0.0001 56 (17.50)
Systolic blood pressure 0.0001 0.0001
100 mm Hg 2,963 (10.14) 96 (51) 452 (15.25)
100–180 mm Hg 23,433 (80.19) 102 (54) 786 (3.35)
180 mm Hg 2,724 (9.32) 112 (57) 53 (1.95)
Unknown 102 (0.35) 117 (69) 38 (37.25)
Heart rate 0.0001 0.0001
50 beats/min 1,766 (6.04) 95 (48) 143 (8.10)
50–100 beats/min 23,969 (82.02) 102 (53) 793 (3.31)
100 beats/min 3,376 (11.55) 113 (64) 355 (10.52)
Unknown 111 (0.38) 118 (65) 38 (34.23)
First assessment of heart failure 0.0001 0.0001
No congestive heart failure 25,908 (88.66) 101 (53) 722 (2.79)
Rales/jugular venous distension 1,895 (6.48) 110 (60) 195 (10.29)
Pulmonary edema 536 (1.83) 124 (76) 105 (19.59)
Cardiogenic shock 883 (3.02) 105 (56) 307 (34.77)Continued on next page
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June 6, 2006:2180–6 Door-to-Balloon Time and Mortalityransferred out and assumed they survived to discharge. To
valuate the potential effect of decreasing length of stay on
ur results, we also performed secondary analyses that
valuated mortality within 72 h. The results of both of these
econdary analyses were not substantially different from the
riginal.
Statistical analyses were performed using SAS version 9.1
SAS Institute Inc., Cary, North Carolina), HLM 5.04 for
indows (SSI, Lincolnwood, Illinois), and Stata version
.0 (Stata Corp., College Station, Texas). The investigators
ad full access to all of the data in the study and take
esponsibility for the integrity of the data and the accuracy
f the data analysis.
ESULTS
ample characteristics. The cohort was predominantly
ale (71%) and white (86%), with a mean age of 61.6 years
Table 1). A substantial proportion of patients had a prior
iagnosis of coronary artery disease and/or traditional car-
iac risk factors. Almost 10% received a prehospital ECG,
4% had chest pain, 11% were in overt heart failure, and 2%
ad left bundle branch block. A total of 62% presented
ithin 2 h of symptom onset. There were 58% of the
atients who had an ACC/AHA high-risk feature (36%
able 1 Continued
Description
Prevalence
n (%)
irst 12-lead ECG
Anterior/septal location 10,631 (36.38)
No. of leads with ST-segment elevation
Left bundle branch block 580 (1.98)
2 3,174 (10.86)
3 and 4 19,609 (67.10)
5 and more 5,565 (19.04)
Unknown 294 (1.01)
First 12-lead ECG: ST-segment
depression
13,758 (47.08)
Nonspecific ST or T-wave deltas 856 (2.93)
Q-wave (acute infarct zone) 3,565 (12.20)
imes
Symptom onset-to-door
1 h 9,487 (32.47)
1–2 h 8,557 (29.28)
2 h 11,178 (38.25)
Time/weekday of the admission day
Weekday 8:00AM–3:59PM 10,916 (37.36)
Weekday 4:00PM–11:59PM 5,690 (19.47)
Weekday 12:00AM–7:59AM 4,827 (16.52)
Weekend 8:00AM–3:59PM 3,639 (12.45)
Weekend 4:00PM–11:59PM 2,412 (8.25)
Weekend 12:00AM–7:59AM 1,738 (5.95)
Calendar time
First year 7,978 (27.30)
Second year 7,238 (24.77)
Third year 7,791 (26.66)
Fourth year 6,215 (21.27)
CG  electrocardiogram.ith anterior/septal location, 19% with diabetes mellitus, (2% with heart rate 100 beats/min, and 10% with systolic
lood pressure 100 mm Hg).
ssociation with in-hospital mortality. In unadjusted
nalysis, many patient characteristics were significantly as-
ociated with both door-to-balloon time and in-hospital
ortality (Table 1). Notable exceptions were race/ethnicity
nd time/day of presentation. In hierarchical multivariable
nalysis, many patient characteristics continued to be sig-
ificantly associated with mortality (Table 2). In particular,
ll four ACC/AHA high-risk factors were associated with
ncreased mortality. In contrast, symptom onset-to-door
ime was not significantly associated with mortality.
oor-to-balloon time and mortality. In-hospital mortal-
ty increased significantly with increasing door-to-balloon
imes (Fig. 1). This relationship was seen in patients
egardless of symptom onset-to-door time (Fig. 2). The
ssociation between shorter door-to-balloon times and
ower mortality was seen both for patients with ACC/AHA
igh-risk factors and for those without these risk factors
Fig. 3). In hierarchical multivariable analysis, the odds of
n-hospital mortality increased with increasing door-to-
alloon time for all subgroups, whether by symptom onset-
o-door time (Fig. 4A) or presence or absence of risk factors
Door-to-Balloon Time
Mortality
edian, min
uartile Range) p n (%) p
104 (55) 0.0001 656 (6.17) 0.0001
0.0001 0.0001
132 (84) 85 (14.66)
118 (67) 129 (4.06)
101 (52) 728 (3.71)
97 (48) 367 (6.59)
109 (62) 20 (6.80)
99 (50) 0.0001 584 (4.24) 0.0190
114 (71) 0.0001 31 (3.62) 0.1867
106 (57) 0.0001 196 (5.50) 0.0037
0.0001 0.0073
96 (50) 462 (4.87)
99 (50) 339 (3.96)
110 (61) 528 (4.72)
0.0001 0.3824
90 (52) 492 (4.51)
105 (51) 280 (4.92)
109 (56) 198 (4.10)
110 (55) 160 (4.40)
109 (49) 120 (4.98)
119 (54) 79 (4.55)
0.0001 0.0531
105 (57) 394 (4.94)
102 (54) 344 (4.75)
100 (53) 339 (4.35)
102 (52) 252 (4.05)M
(QFig. 4B).
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Door-to-Balloon Time and Mortality June 6, 2006:2180–6ISCUSSION
n this large observational study of patients with STEMI
ndergoing primary PCI, we found clear evidence of in-
reased mortality with longer door-to-balloon times. This
ssociation was seen for patients regardless of symptom
nset-to-door time and for patients with and without
igh-risk factors. These findings support the current
uideline-based recommendations for rapid PCI and pro-
ide evidence that this recommendation is valid for all
atients with STEMI and presentation within 6 h of the
nset of symptoms.
ime from symptom onset to reperfusion. Shorter time
rom symptom onset to the administration of fibrinolytic
able 2. Factors Independently Associated With In-Hospital
ortality in Multivariate Hierarchical Logistic Regression
odel (p  0.01)
Description
Odds Ratio
(95% Confidence Interval) p
emographics
Age
65 yrs 0.41 (0.36–0.47) 0.0001
80 yrs 1.98 (1.72–2.27) 0.0001
Female 1.27 (1.14–1.42) 0.0001
edical history
Current smoker 0.74 (0.64–0.84) 0.0001
Chronic renal insufficiency 1.70 (1.36–2.13) 0.0001
Diabetes 1.38 (1.22–1.57) 0.0001
Hypercholesterolemia 0.63 (0.56–0.72) 0.0001
Family history of coronary
artery disease
0.82 (0.71–0.94) 0.0056
Percutaneous coronary intervention 0.74 (0.63–0.88) 0.0005
Coronary artery bypass 1.40 (1.14–1.72) 0.0014
Stroke 1.44 (1.20–1.74) 0.0001
resentation
Chest pain at presentation
No 3.63 (3.13–4.20) 0.0001
Unknown 3.76 (2.76–5.12) 0.0001
Systolic blood pressure
100 mm Hg 3.75 (3.27–4.30) 0.0001
180 mm Hg 0.43 (0.33–0.55) 0.0001
Unknown 4.59 (2.23–9.46) 0.0001
Heart rate
50 beats/min 0.84 (0.69–1.03) 0.0992
100 beats/min 2.31 (2.02–2.64) 0.0001
Unknown 2.27 (1.08–4.75) 0.0299
First assessment of heart failure
Rales/jugular venous distension 2.19 (1.87–2.56) 0.0001
Pulmonary edema 3.30 (2.63–4.14) 0.0001
Cardiogenic shock 7.25 (6.13–8.58) 0.0001
irst 12-lead electrocardiogram
Anterior/septal location 1.81 (1.61–2.03) 0.0001
No. of leads with ST-segment
elevation
Left bundle branch block 2.20 (1.63–2.98) 0.0001
3 and 4 0.98 (0.81–1.18) 0.8147
5 and more 1.44 (1.18–1.77) 0.0005
Unknown 1.43 (0.86–2.38) 0.1659
Q-wave (acute infarct zone) 1.24 (1.06–1.45) 0.0065
imes
Door-to-balloon time per 30 min 1.08 (1.05–1.11) 0.0001herapy has been consistently shown to be associated with
F
bower mortality for patients with STEMI (1–3,17,18).
owever, a meta-analysis of randomized trials found time
rom symptom onset to reperfusion related to mortality for
brinolytic therapy in all patients, but for PCI only in those
reated within 2 h (10). Large single-center observational
tudies have found similar results (4,6). In contrast, analysis
f previous patients in NRMI-1 and -2 found no significant
elationship between symptom onset-to-balloon time and
ortality (7). Similarly, our study of NRMI-3 and -4 did
ot find improved survival for patients with decreased
ymptom onset-to-door time after adjusting for patient
haracteristics. In support of our findings, myocardial sal-
age has been found to be related to time from symptom
nset to fibrinolytic therapy but independent of time from
ymptom onset to balloon (19). In addition to biological
xplanations, methodological issues may account for the
oor relationship. First, the accuracy of the time of symp-
om onset is limited because of patient reporting error.
atients frequently are unsure of the exact time of symptom
nset and usually give an estimate. Second, patients with
ess certainty of time of symptom onset may be more likely
o get PCI than fibrinolytic therapy because of the increased
isk of bleeding for fibrinolytic therapy. Finally, some of the
eaths from STEMI may occur before hospital presenta-
ion. These patients would not be entered into the registry,
igure 1. In-hospital mortality and door-to-balloon time; p for trend 
.001.igure 2. In-hospital mortality and door-to-balloon time in patients stratified
y symptom onset-to-door time; p for trend  0.001 for each line.
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June 6, 2006:2180–6 Door-to-Balloon Time and Mortalitynd their absence likely dilutes the relationship between
ymptom onset-to-door time and mortality.
oor-to-balloon time. We evaluated a subset of the
ymptom onset-to-balloon time, the door-to-balloon time.
n addition to improving the accuracy of estimate, door-to-
alloon time is easier to influence because it is more
igure 3. In-hospital mortality and door-to-balloon time in patients
tratified by risk factor status; p for trend 0.001 for each line. Risk factors
nclude anterior/septal location, diabetes mellitus, heart rate 100 beats/
in, systolic blood pressure 100 mm Hg.igure 4. Independent effect of door-to-balloon time on in-hospital mortality in
eference group: door-to-balloon time 90 min. DTB  door-to-balloon; MInder the control of individual hospitals and physicians
han symptom onset-to-door time (20). As with symp-
om onset-to-balloon time, prior studies evaluating the
ssociation between door-to-balloon time and mortality
ave had mixed results. In the Global Use of Strategies to
pen Occluded Arteries in Acute Coronary Syndromes
GUSTO) IIb trial, 30-day mortality rates increased pro-
ressively with time from randomization to balloon infla-
ion, a close surrogate for door-to-balloon time (8). Analysis
f patients in a prior cohort of NRMI also found increasing
ortality with door-to-balloon times (7). Our study con-
rms this association in patients with more recent data as
ell as in various subgroups of patients.
In contrast, a recent study finding that symptom onset-
o-balloon time was an independent predictor of mortality
ailed to find a similar relationship between door-to-balloon
ime and mortality (4). The discrepancy between these
ndings and those of our study may be explained by the fact
hat only 11% of patients in this single-center study had
oor-to-balloon times 90 min. In contrast, a majority of
atients in the NRMI registry had door-to-balloon times in
xcess of 90 min. A low number of patients with times 90
in may decrease sensitivity of finding a relationship. Insubgroups by (A) symptom onset-to-door time and (B) risk factor status.
 myocardial infarction; SBP  systolic blood pressure.
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nly in those at high risk (5). Our study found increasing
oor-to-balloon time to be related to increasing mortality
or all risk groups. The magnitude of the mortality de-
ended on the baseline risk, but the relationship with time
id not differ.
tudy limitations. Although this database is large and has
een found to be reasonably generalizable (16), there are
imitations. First, as mentioned previously, the time from
ymptom onset is obtained from the patient and may not be
ccurate. However, a more accurate time from symptom
nset likely would not affect the main conclusions regarding
oor-to-balloon time. Second, there may be other risk
actors that we did not examine that could identify a
ubgroup of patients in which door-to-balloon time is not
mportant. Third, most of the patients were treated with
oor-to-balloon times greater than guideline recommenda-
ions. The importance of further reductions beyond 90 min
as not been clarified. Fourth, these results cannot be
xtended to patients transferred from one hospital to an-
ther. Finally, door-to-balloon time may be a proxy for
eneral quality of care, with the relationship with mortality
eflecting unobserved quality measures.
tudy implications. Efforts should continue to decrease
he door-to-balloon time for all patients with STEMI
ndergoing primary PCI. Degree of urgency should not
epend on time of symptom onset or baseline risk factors.
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